

November 5, 2009

Astellas Announces Acquisition of Treasury Stock

(Acquisition of treasury stock pursuant to the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Japan, November 5, 2009 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its treasury stock pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

1. Reasons for the acquisition of treasury stock
To improve capital efficiency and enhance return to shareholders.

2. Contents of acquisition
 - (1) Class of shares to be acquired: Common stock of the Company
 - (2) Total number of shares to be acquired: 8.2 million shares (maximum)
(The percentage compared to the total number of shares outstanding: 1.74%)
 - (3) Aggregate amount of acquisition cost: 30 billion yen (maximum)
 - (4) Period of acquisition: From November 9, 2009 to December 11, 2009

(Reference)

The status of treasury stock as of September 30, 2009:

Total number of shares outstanding: 470,014,807 shares

Number of treasury stock: 5,949,828 shares

#####

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com